Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.65 |
| ▸ | HTR2C | P28335 | 10/20 | 0.57 |
| ▸ | HTR2B | P41595 | 6/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16356786 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL16356787 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL1289737 | 0.81 | SLC6A4 (0.67) | SLC6A4HTR2CHTR2BHTR2AMAOB | |
| SCHEMBL777102 | 0.81 | HTR2C (0.59) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL8005380 | 0.80 | HTR2C (0.49) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL8005382 | 0.80 | HTR2C (0.49) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL8005384 | 0.80 | HTR2C (0.49) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL147285 | 0.79 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL12511292 | 0.76 | MAOA (0.45) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL7969639 | 0.75 | ALOX5 (0.53) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4478836-A | 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system | PIERRE FABRE S.A. (FR) | 1984-10-23 | — | — | US | disclosed |